A Culturally Sensitive Social Support Intervention
Not Applicable
Completed
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- Behavioral: Social support intervention
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT02946697
- Locations
- 🇺🇸
Herald Cancer Association, Los Angeles, California, United States
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Not Applicable
Recruiting
- Conditions
- Estrogen Receptor NegativeHER2 Positive Breast CarcinomaHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- Radiation: External Beam Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentRadiation: Whole Breast IrradiationOther: Questionnaire Administration
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT02945579
- Locations
- 🇺🇸
MD Anderson Cancer Center - Banner, Gilbert, Arizona, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸Queen's Medical Center, Honolulu, Hawaii, United States
Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II
Early Phase 1
Withdrawn
- Conditions
- Smoking Cessation
- Interventions
- Behavioral: QuestionnaireBehavioral: In-Depth InterviewsOther: Breath TestBehavioral: Advice plus Phone CounselingBehavioral: Advice plus Counseling SessionsBehavioral: Self Assessment Questionnaires
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02942212
- Locations
- 🇺🇸
Literacy Advance of Houston, Houston, Texas, United States
Study of Ixazomib and Erlotinib in Solid Tumors
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02942095
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
Phase 2
Completed
- Conditions
- BCLC Stage B Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7BCLC Stage C Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Refractory Liver CarcinomaStage IVB Hepatocellular Carcinoma AJCC v7Hepatitis C InfectionStage IIIA Hepatocellular Carcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Pembrolizumab
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02940496
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
Phase 2
Terminated
- Conditions
- Advanced Malignant NeoplasmFatigue
- Interventions
- Behavioral: Exercise InterventionOther: PlaceboOther: Laboratory Biomarker AnalysisBehavioral: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT02940223
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Phase 2
Completed
- Conditions
- Cancer
- Interventions
- Other: High-flow OxygenOther: Low-flow OxygenOther: High-flow AirOther: Low-flow Air
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT02932332
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Phase 1
Completed
- Conditions
- Resectable Pancreatic CarcinomaStage I Pancreatic Cancer AJCC v6 and v7Stage IA Pancreatic Cancer AJCC v6 and v7Stage IB Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: PembrolizumabProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02930902
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2
Terminated
- Conditions
- Fallopian Tube AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaMalignant Ovarian Brenner Tumor
- Interventions
- Biological: BevacizumabBiological: EmactuzumabOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02923739
- Locations
- 🇺🇸
MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer
Not Applicable
Completed
- Conditions
- Disorders of Breast
- Interventions
- Other: ExerciseBehavioral: QuestionnairesBehavioral: Motivational SessionBehavioral: Phone CallOther: Printed Materials
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02923401
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath